• Royalty Pharma held its annual general meeting on June 4, 2026.
• Shareholders adopted resolutions appointing nine directors to serve until the 2027 annual meeting.
• Ernst & Young LLP was ratified as independent registered public accounting firm; Ernst & Young was also re-appointed as U.K. statutory auditor.
• Resolutions were adopted to receive the U.K. annual report and accounts for the year ended Dec. 31, 2025, including the statutory reports.
• Shareholders authorized the board to set the U.K. auditor’s remuneration, buy back Class A shares, allot shares, and allot shares without pre-emption rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-257432), on June 04, 2026, and is solely responsible for the information contained therein.